Browse studies

Find your next paid study

1,847 recruiting studies matching your filters

Newest first Highest paying

Phase 1

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma

Ovarian Clear Cell Carcinoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06065462

Observational

A Community-Engaged Approach to Culturally Adapting an Intervention to Increase Uptake of Genetic Testing Among African American Cancer Survivors

The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing …

Female Breast CancerProstate CancerColorectal Carcinoma

Estimated

~$10 – $7,500

Barbara Ann Karmanos Cancer InstituteNCT07436078

Observational

PROACT: Promoting Follow-Up of Abnormal Colorectal Cancer Screening Tests Through Multilevel Interventions

This clinical trial studies whether an intervention that addresses two or more levels of care (multilevel intervention) increases follow-up of abnormal, non-in…

Colorectal Carcinoma

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT06822530

Phase 2

A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the freque…

HER2/Neu+ Uterine Serous Carcinoma

Estimated

~$10 – $6,250

Yale UniversityNCT02491099

Phase 2

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patie…

Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)Head and Neck Squamous Cell Carcinoma HNSCC

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07659678

Phase 2

Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer

This phase II trial tests how well photoimmunotherapy (PIT) with ASP-1929 in combination with cemiplimab works in treating patients with stage IIIB-IV non-smal…

Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+3 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06943664

Phase 1

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how w…

Metastatic Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04071236

Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other ca…

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Lung Carcinoma+7 more

Estimated

~$10 – $750

Mayo ClinicNCT06075524

Phase 1

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary eff…

Esophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more

Estimated

~$10 – $8,750

IDEAYA BiosciencesNCT07503808

Phase 1

A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GB-4362 Administered With Enfortumab Vedotin and Pembrolizumab in Participants With Advanced Urothelial Cancer

The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedoti…

Advanced Urothelial CancerMetastatic Urothelial Carcinoma

Estimated

~$10 – $7,500

Generate BiomedicinesNCT07484022

Phase 1

Phase I Clinical Trial of Autologous Folate Receptor-Alpha Redirected T Cells in Patients With FRa+ Cancers

This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells…

Metastatic Non Small Cell Lung CancerRecurrent Lung Non-Small Cell Carcinoma

Estimated

~$10 – $6,250

University of PennsylvaniaNCT07116057

Phase 2

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - A Randomized Trial (DESTINATION 2)

The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compa…

Prostate CancerProstate Adenocarcinoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07635238